GH Research (GHRS) announced that, in June, it submitted its complete response to the previously announced clinical hold of its Investigational New Drug Application for GH001 to the U.S. Food and Drug Administration. “We are thrilled to have submitted our response to the FDA ahead of schedule, addressing their clear requests with comprehensive data and completed toxicology studies. We remain fully committed to working closely with the agency to bring GH001 to patients,” said Dr. Velichka Valcheva, CEO.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GHRS:
- GH Research Announces AGM and Key Resolutions for July 2025
- Trump Trade: President said to weigh possible U.S. strike against Iran
- Psychedelic advocates hopeful Trump administration will support space, STAT says
- GH Research to Participate in Neuro Perspectives Conference
- Psychedelic: atai, Beckly Psytech to combine in all-share transaction